No Data
No Data
Scotiabank Maintains Tempest Therapeutics(TPST.US) With Buy Rating, Maintains Target Price $13
Scotiabank Keeps Their Buy Rating on Tempest Therapeutics (TPST)
Sector Update: Health Care Stocks Rise Late Afternoon
Top Midday Gainers
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
Tempest Jumps as FDA Aligns With Trial Design for Cancer Drug
No Data
Lnova :![heart_eyes 😍](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f60d.png)